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ABSTRACT 
 
Ion channels regulate cell proliferation, differentiation, and migration in normal and 
neoplastic cells through cell-cell and cell-extracellular matrix (ECM) transmembrane receptors 
called integrins. K
+
 flux through the human ether-à-go-go-related gene 1 (hERG1) channel shapes 
action potential firing in excitable cells such as cardiac myocytes. Its abundance is often aberrantly 
high in tumors, where it modulates integrin-mediated signaling. We found that hERG1 interacted 
with the 1 integrinsubunit at the plasma membrane of human cancer cells. This interaction was 
not detected in cardiac myocytes because of the presence of the hERG1 auxiliary subunit KCNE1 
(potassium voltage-gated channel subfamily E regulatory subunit 1), which, blocked the 1 
integrin-hERG1 interaction. Although open hERG1 channels did not interact as strongly with 1 
integrins as did closed channels, current flow through hERG1 channels was necessary to activate 
the integrin-dependent phosphorylation of Tyr
397
 in Focal Adhesion Kinase (FAK) in both normal 
and cancer cells. In immunodeficient mice, proliferation was inhibited in breast cancer cells 
expressing forms of hERG1 with impaired K
+
 flow whereas metastasis of breast cancer cells was 
reduced when the hERG1/1 integrin interaction was disrupted. We conclude that the interaction of 
1 integrins with hERG1 channels in cancer cells stimulated distinct signaling pathways that 
depended on the conformational state of hERG1 and affected different aspects of tumor 
progression. 
 
 
 
 
INTRODUCTION 
 
Cell adhesion to the extracellular matrix (ECM) is critical to various processes, including 
cell migration, synaptic plasticity, and the decision between proliferation and differentiation (1, 2). 
Both voltage- and ligand-gated ion channels regulate how cells respond to the ECM by interacting 
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with integrin receptors (3, 4). Integrin receptors are transmembrane proteins consisting of various α 
and β subunits. In mammals, they can form more than twenty different heterodimers with specific 
ECM binding patterns (5, 6). Under resting conditions, integrin receptors reside in a folded low-
affinity conformational state. Upon activation by extracellular or intracellular ligands or binding 
partners, they shift to a high-affinity extended conformation (7, 8), which mediates both ‘outside-in’ 
and ‘inside-out’ signaling (5). An important early signal triggered by integrin engagement is 
phosphorylation of focal adhesion kinase (FAK), which in turn regulates downstream signaling (9). 
A common molecular partner of integrin receptors is the human ether-à-go-go-related gene 1 
protein (hERG1, also known as Kv11.1). In cardiac myocytes, hERG1 mediates the cardiac 
repolarizing current Ikr (10) in association with accessory subunits such as the potassium voltage-
gated channel subfamily E regulatory subunit 1 (KCNE1, also known as MinK1). Moreover, 
hERG1 regulates excitability in the central nervous system, endocrine cells and smooth muscle (11, 
12). However, information about the interaction between integrin receptors and hERG1 is available 
only for neoplastic cells. The abundance of hERG1 is often aberrantly high in human cancers, and 
this channel is implicated in different stages of neoplastic progression, such as cell proliferation and 
survival, invasiveness, and neo-angiogenesis (12-14). Because these processes are regulated by cell 
adhesion to ECM, the crosstalk between integrin receptors and hERG1 may constitute a unifying 
modulatory mechanism of the cellular response to the microenvironment in both normal and tumor 
tissue (4, 15). 
Integrin receptors and ion channels communicate by diffusible signals (16-20) as well as by 
forming macromolecular complexes (21-25). In particular, the β1 integrin-mediated adhesion to 
fibronectin activates hERG1 currents (IhERG1) in different cell types (17, 26). In neuroblastoma cells, 
this process is mediated by Gi protein (17) and triggers integrin-dependent signaling cascades (23, 
26). In addition, cell adhesion to fibronectin generally stimulates the formation of a macromolecular 
complex between hERG1 and β1 integrin (hERG1/1 integrin complex) (23), which may recruit 
growth factor receptors such as the vascular endothelial growth factor receptor-1 (VEGFR-1) (27), 
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and the C-X-C motif chemokine receptor 4 (CXCR-4) (28). Therefore, hERG1 takes part in multi-
protein complexes that constitute major signaling centers in different cell types. 
How hERG1 and β1 integrin interact and how the ensuing macromolecular complex 
responds to diffusible signals is unknown. The role of K
+
 flow as compared to non-conductive 
hERG1-related signals is also unclear. Here, we first investigated why the hERG1/1 integrin 
complex was formed in cancer cells, but not in heart tissue, where hERG1 is found with its ancillary 
subunits (11). Next, we studied the mechanism of interaction of the two proteins using deletion 
mutants. The protein-protein interaction was further confirmed with Förster Resonance Energy 
Transfer (FRET) analysis (29-32). Using hERG1 mutants with alterations in either conductance or 
gating, we sought to discriminate between the contributions of the channel’s conformational state 
and K
+
 flow to the assembly of the macromolecular complex and to downstream signaling. Finally, 
we studied the in vivo effects of disrupting the interaction between hERG1 and β1 integrin on the 
growth and metastasis of breast cancer cells xenografted in mice. 
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RESULTS 
 
KCNE1 and 1 integrin compete for binding to hERG1 
We compared the interaction between hERG1 and β1 integrin in primary cancer samples and 
surgical samples from human hearts. β1 integrin immunoprecipitates from colorectal cancers 
(CRC), pancreatic cancers (PC), acute myeloid (AML) and chronic myeloid (CML) leukemias 
contained a hERG1 band (Fig. 1A, left panel). Conversely, a β1 integrin band was detected in 
hERG1 immunoprecipitates from CRC, PC and CML-1 samples (Fig. 1A, right panel). In contrast, 
no association between hERG1 and β1 integrin was detected in cardiac tissue from human atria 
(Fig. 1B). Because hERG1 associates with KCNE1 in cardiac myocytes (10, 33), we hypothesized 
that the ancillary protein could impair the channel interaction with 1 integrin. We first verified that 
both hERG1 (Fig. 1B, input hERG1) and KCNE1 (Fig. 1C) were present in the heart samples. In 
contrast, neither the KCNE1 transcript nor the corresponding protein was found in the tumor cell 
lines with a hERG1/1 integrin complex (Fig. 1C) (26, 27). Next, we expressed KCNE1 in 
HCT116 cells, which have endogenous hERG1, or HEK 293 (HEK) cells, which lack the potassium 
channel and were transfected with hERG1. The presence of transcript for KCNE1 was verified by 
Real Time Quantitative PCR (RT-qPCR) (Fig. S1, A and B). In HEK cells plated on fibronectin, 
the formation of the hERG1/1 integrin complex was inhibited by KCNE1 (Fig. 1D). Similar 
results were obtained in HCT116 cells (Fig. 1E), although the effect was smaller. These results 
suggested that KCNE1 and 1 integrin competed for binding to hERG1, which could explain why 
formation of the hERG1/1 integrin complex occurs only in neoplastic tissue. 
 
hERG1 and β1 integrin may directly physically interact  
To study how hERG1 and β1 integrin assemble, we used HEK cells transfected with wild-type 
(HEK-hERG1) or mutant hERG1 cDNA. Endogenous 1 integrin is present in these cells and co-
immunoprecipitated with hERG1 in cells allowed to adhere to fibronectin (23) (Fig. S2). To study 
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whether the two proteins interacted directly, we applied Hyperspectral-Fluorescence Lifetime 
Imaging Microscopy-FRET (HS-FLIM-FRET) (34), on HEK cells transfected with CFP-labeled 
hERG1 and YFP-labeled β1 integrin (Fig. S3). The fluorescence decay was characterized by bi-
exponential behavior with one long-lived and one fast decaying component. From each cell (Fig. 
2A), we obtained the lifetimes (τs and τf, respectively) and fraction size (As and Af) of both 
components for all pixels of the image (control experiments are in Fig. S4 and Fig. S5). The slow 
lifetime was similar to the lifetime of eCFP when no energy transfer occurred (τs = 2.48 ± 0.09 ns, 
see Supplementary Materials). The fast lifetime is a signature of energy transfer and the close 
proximity of hERG1 to β1 integrin. By using equation (2) (Supplementary Materials and Methods), 
the calculated FRET efficiency was 0.77 ± 0.04. We also compared the HS-FLIM-FRET signals in 
cells cultured onto fibronectin or bovine serum albumin (BSA). Measurements were stopped at 100 
min, because after that time cells cultured onto BSA progressively detached from the substrate. The 
donor mean lifetime values (τm) was calculated using eq. (3) (Supplementary Materials). For cells 
cultured on fibronectin τm was 1.71 ± 0.05, whereas for cells cultured on BSA τm was 2.00 ± 0.08 
(Fig. 2B). Shorter lifetimes in cells cultured onto fibronectin indicated higher FRET efficiency in 
elongated cells that strongly adhered to the substrate (Fig. 2C, FRET). In contrast, longer lifetimes, 
which indicated lower FRET efficiency or no FRET, corresponded to round cells or cells fixed to 
the substrate through small filopodia (Fig. 2C, NO FRET).  
 
The hERG1/1 integrin complex is localized to the plasma membrane 
To demonstrate that hERG1 and 1 integrin interaction occurred at the plasma membrane, the 
functional site of both proteins, we performed FRET experiments by acceptor photobleaching 
imaging (29) on fixed HEK cells. Donor and acceptor were labeled using monoclonal antibodies 
directed against hERG1, which was coupled to AlexaFluor488, and against 1 integrin, which was 
coupled to AlexaFluor546 (Fig. S6 and Fig. S7). Confocal imaging allowed us to image FRET at 
various locations in the cell. We chose two different focal planes, one located at the plasma 
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membrane close to the fibronectin-coated substrate (Fig. 2D, Bottom plasma membrane), and one 
located at approximately half of the maximal cell thickness (Fig. 2D, Z-slice plasma membrane). 
Data analysis confirmed that the FRET signal originated on, or was proximal to, the plasma 
membrane (acceptor mask in Fig. S7B). The average FRET efficiencies calculated for the bottom 
and the equatorial (Z-slice) plasma membranes were similar (Fig. 2E). Hence, the interaction 
between hERG1 and 1 integrin was not restricted to the membrane portions involved in cell-
substrate adhesion, but also occurred in membrane patches distant from the adhesion sites. The 
mean FRET efficiency for both locations was 0.24 ± 0.05,  about 4-fold smaller than the value 
measured by HS-FLIM-FRET, which we attribute to the different labeling methods for hERG1 and 
1 integrin.  
 
Interaction between hERG1 and 1 integrin does not require the hERG1 intracellular 
domains or the cytoplasmic C-terminal domain of 1 integrin 
To define the molecular domains implicated in complex formation, we performed 
electrophysiological analysis of HEK cells stably expressing forms of hERG1 lacking the entire N-
terminus (hERG1Δ2-370) or the C-terminus (hERGΔC+RD) except for the amino acids from 1018 
to 1122, which constitute the Recapitulation Domain (RD) that allows hERG1 insertion into the 
plasma membrane (35). As expected, whole-cell current recordings indicated that hERG1Δ2-370 
displayed the typical fast deactivation conferred by N-terminus deletion (36), whereas 
hERG1ΔC+RD generally displayed current amplitudes considerably smaller than those of hERG1 
(35) (Fig. 3A). Immunoprecipitation analysis of these cells suggested that the cytoplasmic hERG1 
domains were dispensable for assembly with 1 integrin (Fig. 3B). To test if the intracellular 
domain of 1 integrin interacted with hERG1, we transfected hERG1 and the following YFP-
labeled constructs into GD25 cells, which are deficient in 1 integrins (37): (i) full-length 1 
integrin, (ii) 1 integrin lacking the C-terminus (1-extra) and (iii) 1 integrin C-terminus linked to 
 9 
the transmembrane and extracellular portions of the interleukin-2 receptor (1-cyto) (Fig. 3C, 3D). 
Co-immunoprecipitation analysis showed that hERG1 co-immunoprecipitated with 1 integrin and 
1-extra, but not with 1-cyto (Fig. 3D), suggesting that the cytoplasmic domain of 1 integrin was 
not necessary for interaction with hERG1. We confirmed this conclusion by performing co-
immunoprecipitation using an antibody against 1 integrin in GD25-1-TR cells, which stably 
express 1 integrin lacking the C-terminus (Fig. 3E). We concluded that the cytoplasmic domains 
of hERG1 and 1 integrin were not necessary for the interaction of these proteins. 
 
HERG1 gating, but not conduction, regulates the complex formation. 
The results obtained with hERG1ΔC+RD (Fig. 3A and 3B) suggested that impairing channel 
conduction did not affect the association of hERG1 with β1 integrin. To further investigate this 
issue, we tested the complex formation in the presence of E4031, which blocks hERG1 (Fig. 4A) by 
binding to the Phe
656
 residue that protrudes into the channel pore (38). E4031 inhibited the complex 
formation by about 80% (Fig. 4B). This result could be explained if K
+
 flux is critical for complex 
formation, or if the presence of E4031 locks a substantial fraction of the channels in the open 
conformation, which may have a lower affinity for β1 integrin. To better distinguish these 
mechanisms, we expressed several mutant constructs in HEK cells: the non conducting hERG1-
G628S (38), hERG1-R531C and hERG1-K525C, which are S4 domain mutants with altered 
activation (39), and the non-inactivating hERG1-S620T (40). Flow cytometry analysis (41) 
indicated that the plasma membrane abundance of the mutants was ~25-30% less compared to wild-
type hERG1 (Fig. 4C). The strong decrease in K
+
 flow for the hERG1-G628S mutant is not 
accompanied by gating alterations (38). hERG1-G628S current amplitudes were comparable to 
those displayed by hERG1 in the presence of E4031 (Fig. 4D). Cells expressing hERG1-G628S had 
a mean membrane voltage (Vm) in resting conditions (Vrest) of -36.9 ± 1.9 mV, compared to -48.4 ± 
2.3 mV in cells expressing wild-type hERG1. Formation of the hERG1/β1 integrin complex was not 
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significantly impaired by hERG1-G628S (Fig. 4E). Thus, although blocking channel conduction 
with E4031 impaired the complex assembly, data obtained with the non-conducting hERG1-G628S 
mutant suggested that decreased current flow per se was not the main determinant of the effect, in 
agreement with the results obtained with hERG1ΔC+RD.  
To test the alternative hypothesis that the complex formation is sensitive to the channel’s 
conformational state, we used mutants with different steady-state activation properties (Fig. 5A). 
Like wild-type hERG1, the hERG1-K525C protein was detected at the plasma membrane (Fig. 4C) 
although the maximal current density was lower (Fig. 5B)  and the activation curve was shifted to 
more negative Vm (Fig. 5C). In agreement with previous work (39), the estimated V1/2 of activation 
was around -50 mV, and the measured Vrest was -59.1 ± 1.1. Hence, at steady state, hERG1-K525C 
channels spend more time in the open state than wild-type hERG1. hERG1-R531C had a similar 
maximal current density to that displayed by wild-type hERG1 (Fig. 5B). The estimated V1/2 of 
activation was approximately +35 mV (Fig. 5C). The corresponding Vrest was -42 ± 2.6 mV, 
implying that a large fraction of hERG1-R531C channels resided in the closed state in our cells. Co-
immunoprecipitation analysis showed that less β1 integrin associated with hERG1-K525C than 
with wild-type hERG1 or hERG1-R531C (Fig. 5D). This result suggested that increasing the 
probability of the channel being in the open state decreased complex formation. To further test this 
hypothesis, we used the non-inactivating hERG1-S620T mutant, in which the open-closed transition 
is not complicated by the presence of the inactive state (40). Consistent with the absence of 
inactivation (Fig.5A), hERG1-S620T had a maximal current density of 447 ± 89 pA/pF (Fig.5B), 
considerably higher than that measured for wild-type hERG1, and the measured Vrest was -59 ± 2.3 
mV. Similarly to hERG1-K525C, the complex association of hERG1-S620T with 1 integrin was 
impaired compared to wild-type hERG1 (Fig. 5E). These results are consistent with the hypothesis 
that assembly of the hERG1/1 integrin complex was hindered when the probability of the channel 
transition towards the open state increased. 
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This mechanism was further investigated by FRET experiments in acceptor photobleaching 
setting, on HEK cells expressing either wild-type hERG1, or hERG1-R531C, or hERG1-K525C. 
The FRET efficiency distributions for the three conditions were not statistically different (Fig. 5F), 
demonstrating that energy transfer took place in both hERG1-R531C and hERG1-K252C 
transfected cells. This finding suggested that the hERG1/1 integrin complex, once it formed, was 
structurally similar in wild-type and mutant channels. Next, we determined the percentage of FRET 
events, which reflected the abundance of hERG1/1 integrin complexes. In agreement with the co-
immunoprecipitation data, complex formation was significantly impaired in cells expressing 
hERG1-K525C (Fig. 5G). Remarkably, these findings did not depend on the relative ratio between 
donor (hERG1) and acceptor (1 integrin) present in the membrane (Fig. S8). 
 
hERG1 current flow regulates FAK phosphorylation and cell proliferation in vivo 
We have previously shown that the β1 integrin-dependent FAK phosphorylation in HEK 
cells expressing wild-type hERG1 relies on hERG1 activation (23). Hence, we studied how this 
process was modified by either E4031 or by the mutant channels. FAK was immunoprecipitated 
from HEK cells expressing wild-type hERG1 (treated or not with E4031) or one of the mutant 
hERG1 channels (Fig. 6A). The phosphorylation of Tyr
397 
in
 
FAK (23) was impaired in cells 
expressing mutant hERG1 channels, with the exception of hERG1-S620T, compared to that in HEK 
cells expressing wild-type hERG1 (Fig. 6A). This finding suggests that the integrin-dependent FAK 
auto-phosphorylation required physiological hERG1 current amplitudes, which was impaired for 
different reasons by hERG1-G628S, E4031, hERG1-K525C and hERG1-R531C, but not by 
hERG1-S620T. Because FAK controls various cellular functions, including cell survival and 
proliferation (42), by activating numerous signaling pathways, we tested the effects of the above 
treatments on in vivo cell growth. We subcutaneously injected HEK cells expressing wild-type 
hERG1, hERG1-G628S, hERG1-K525C or hERG1-R531C into immunodeficient nude mice. In 
mice that received cells expressing the different mutants or expressing wild-type hERG1 in the 
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presence of E4031, the growth of subcutaneous masses was reduced compared to mice injected with 
HEK cells expressing wild-type hERG1 (Fig. 6B). 
 
Disrupting the hERG1/1 integrin complex inhibits metastasis of breast cancer cells 
We next tested whether such hERG1-mediated cell signals were present in cancer cells in which the 
abundance of hERG1 is abnormally high and in which hERG1 forms a macromolecular complex 
with β1 integrin (26, 28).  Specific hERG1 blockade with either Way 123,398 (WAY) or E4031 
impairs the phosphorylation of Tyr
397 
in FAK (23,26-28). This process was also studied in MDA-
MB-231 breast cancer cells. Because these cells have low amounts of hERG1, we transfected our 
wild-type and mutant hERG1 constructs, which approximately doubled the membrane amount of 
hERG1 channels (Fig. 7A). Once again, only hERG1-K525C strongly impaired the hERG1/1 
integrin complex formation (Fig. 7B), whereas both hERG1-R531C and hERG1-K525C impaired 
the integrin-dependent phosphorylation of Tyr
397
 in FAK (Fig. 7C). We concluded that the 
signaling interaction between hERG1 and 1 integrin was similar in HEK and cancer cells. 
Finally, we studied the effects of disrupting the hERG1/1 integrin complex in vivo, by using 
MDA-MB-231 breast cancer cells transfected with either hERG1, or hERG1-K525C, or hERG1-
R531C. Cells were injected into either the right or left fourth breast of Severe Combined 
Immunodeficiency Disease (SCID) mice. The number of breasts displaying tumor masses, the 
median volume of the tumor masses, the presence of metastases in inguinal lymph nodes and lungs 
were determined 5 weeks after injection (Fig. 7D and Fig. S9). Although the growth of tumors 
formed from MDA-MB-231 cells was not affected by overexpression of either mutant, the 
percentage of mice with metastases in either the inguinal lymph nodes or in the lungs (Fig. 7D and 
Fig. 7E) was significantly decreased when the cells expressed hERG1-K525C. The percentage of 
metastatic area (Fig. 7F) and the number of metastatic clusters (Fig. 7G) was decreased in mice 
injected with MDA-MB-231 cells expressing hERG1-K525C, compared to those injected with cells 
expressing either wild-type hERG1 or hERG1-R531C. These results suggested that disrupting the 
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hERG1/1 complex by overexpressing the hERG1-K525C mutant impaired the metastatic process.
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DISCUSSION 
We used co-immunoprecipitation experiments and FRET imaging to examine whether 
hERG1 and β1 integrin interacted directly on the plasma membrane. HS-FLIM-FRET showed an 
increase in the fast lifetime component in cells seeded and spread onto fibronectin. The high FRET 
efficiency suggests that the two proteins were in close proximity, within the upper limit of the CFP-
YFP dynamic range of 7.3 nm (43). Whether proximity was caused by direct interaction or through 
the participation of other proteins in a multiprotein complex cannot be distinguished. The 
interaction was increased by cell adhesion on fibronectin. FRET experiments further demonstrated 
that hERG1 and 1 integrin interaction occurred only at the plasma membrane and not in cytosolic 
compartments. Moreover, co-immunoprecipitation experiments showed that hERG1 and 1 integrin 
interacted on the plasma membrane in a manner that did not require the cytoplasmic domains of 
these proteins. Nevertheless, because the hERG1 C-terminus regulates channel gating, an indirect 
contribution to the complex formation cannot be ruled out. Although we did not provide evidence 
excluding that the two proteins interact through their extracellular domains, we favor the conclusion 
that the interaction takes place largely through the transmembrane portions. First, it seems unlikely 
that the highly extended open conformation of the activated integrin (44) would interact 
substantially with the very short extracellular domain of hERG1. Second, the interaction between 
the transmembrane domains would seem more consistent with the gating-dependence of the 
complex formation and the competition between 1 integrin and KCNE1. The transmembrane 
domain of 1 integrin is a short helix, which also undergoes profound conformational changes 
upon integrin engagement (45), and could interact with the hERG1 domains that constitute the 
voltage sensor (11).  
Instead, we found that assembly of this macromolecular complex depended on the channel’s 
conformational state. We derived this conclusion by comparing the degree of complex formation of 
wild-type and mutant hERG1 channels. From the respective steady-state activation curves (39, 40) 
(Fig. 5A and 5C), hERG1 and hERG1-R531C should primarily reside in the closed (deactivated) 
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state, whereas hERG1-K525C and the non-inactivating hERG1-S620T should spend more time in 
the open state. Because the latter two mutants associated poorly with 1 integrin, we concluded that 
complex formation was hindered when hERG1 was in the open state. Consistent with this notion, 
we observed impairment of complex formation in the presence of E4031 (Fig. 4A), which occupies 
the channel pore and thus maintains hERG1 in the open conformational state (11). Our 
interpretation is consistent with the results obtained with the non-conducting hERG1-G628S 
mutant, which shows impaired current flow but a greater ability to interact with β1 integrin than 
hERG1-K525C, hERG1-S620T, or wild-type hERG1 inhibited by E4031. 
On the other hand, most of the conditions we tested tended to block the phosphorylation of 
Tyr
397 
in FAK (namely, auto-phosphorylation), which we used as an early marker of integrin-
dependent downstream signaling. The common outcome of our treatments was a decrease in current 
flow through hERG1. E4031 blocked the channel pore; hERG1-G628S had a very low intrinsic 
channel conductance; hERG1-R531C had a very low open probability at the Vrest typical of our 
cells; hERG1-K525C, although generally active at Vrest, tended nonetheless to display lower whole-
cell current amplitude than wild-type hERG1. The exception was hERG1-S620T, which generated 
higher whole-cell current amplitude than that of wild-type hERG1 (Fig. 5A and 5B).Consistently 
with our interpretation, phosphorylation of Tyr
397 
in FAK in cells expressing this mutant was 
similar to that in cells expressing wild-type hERG1. 
We showed that these mechanisms operated in cancer cells. In all conditions in which IHERG1 
was impaired, in vivo tumor growth was decreased, suggesting that channel activation regulated cell 
proliferation, possibly by controlling signaling pathways downstream of FAK activation (42, 46). In 
contrast, disrupting the hERG1/1 integrin complex impaired the metastatic process of breast 
cancer cells. Therefore, the molecular association between hERG1 and 1 integrin appears to 
modulate the intracellular machinery related to cancer cell migration and invasiveness. Another 
biologically relevant finding was that hERG1/1 integrin complex was not detected in cardiac 
myocytes, which suggests that the complex could be specific to tumor tissue. This difference could 
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be caused by direct competition between 1 integrin and the hERG1 ancillary subunit KCNE1 in 
cardiac myocytes (Fig. 1).The competition between KCNE1 and 1 integrin for hERG1 binding 
suggests that integrins could substitute for KCNE1 as a binding partner in certain tissues. 
Nonetheless, current evidence does not exclude the possibility that KCNE1 also binds to 1 
integrin.  
Our present working hypothesis is that β1 integrin-dependent cell signaling leading to 
autophosphorylation of FAK is regulated by hERG1 activation and requires normal current flow 
through the ion channel, whereas the membrane macromolecular complex tends to recruit hERG1 
channels residing in the non-conducting states. As suggested by single cell analysis (16, 17), 
hERG1 reaches maximal stimulation within a few minutes of cell adhesion onto fibronectin. It is 
possible that hERG1 activation occurring early during the process of cell adhesion has a role in 
stimulating FAK phosphorylation and the ensuing signaling pathways, whereas the late formation 
of the macromolecular complex progressively shifts the hERG1 channel population towards the 
non-conducting state. This process would turn off the early signaling cascade and favor late 
integrin-dependent cytoskeleton reorganization towards migration and invasion (7-8, 46). Hence, 
these results open the way for studies aimed at developing hERG1-related pharmacological 
compounds targeting different aspects of the neoplastic progression. 
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MATERIALS AND METHODS 
 
Chemicals and antibodies 
Unless otherwise indicated, chemicals and antibodies were purchased from Sigma Aldrich (Milan, 
Italy). Cell Lysis Buffer for protein extraction was from Cell Signaling Technology (#9803) and 
Protein A/G-Plus Agarose, for immunoprecipitation, was from Santa Cruz Biotechnology (sc-
2003). The following antibodies were used for immunoprecipitation (IP) and WB, at the indicated 
concentrations. Monoclonal antibody (Mab)-hERG1 (DT-331, Dival Toscana Srl); IP: 5 μg/mg 
protein. Rabbit polyclonal antibody against hERG1 C-terminus (hERG1 CT pan pAb, Dival 
Toscana Srl DT-552); WB, 1:1000. Rabbit polyclonal antibody against β1 integrin C-terminus 
(RM12, Immunological Science); WB, 1:1000. Mab-β1 (TS2/16, Biolegend); IP, 5 μg/mg protein. 
Rabbit polyclonal antibody against GFP/YFP (Ab290, AbCam); WB, 1:1000. Rabbit polyclonal 
antibody against total FAK (SC-8312, Santa Cruz Biotechnology); IP, 1 μg/mg protein; WB, 
1:1000. Rabbit monoclonal antibody against total FAK (EP695Y, AbCam); IP, 6 μg/mg protein; 
WB, 1:1000. Rabbit polyclonal antibody against p-Tyr
397
FAK (BioSource International); WB, 
1:1000. Mouse monoclonal antibody against KCNE1 (Abcam); WB, 1:500. Rabbit polyclonal 
antibody against human MHC class I (H-300) (sc-25619, Santa Cruz); immunohistochemistry, 
1:100. Secondary antibodies for WB: Anti-rabbit IgG peroxidase antibody (whole molecule, 
A0545) 1:10000 and Anti-mouse IgG peroxidase antibody (whole molecule, A4416) 1:5000. 
The hERG1 inhibitor E4031 was used as previously described (23) at a final concentration of 40 
μM, except for the patch-clamp experiments shown in Fig. 4A, where E4031 was used at 2 μM. 
 
Plasmids 
To produce the pECFP-hERG1 plasmid, the full hERG1 cDNA sequence was subcloned from 
pcDNA3.1(+)hERG1 into pECFP-N3 plasmid. Before cloning, to maintain the correct frame 
between ECFP and hERG1, two nucleotides were inserted between a Hind III recognition site and 
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the hERG1 start codon: a 500 bp PCR fragment of hERG1 cDNA was amplified from 
pcDNA3.1(+)hERG1 plasmid using the forward primer TAAGCTTGGATGCCGGTGCGGAGG, 
with a Hind III recognition site (bold) at the 5’ end of fragment, the hERG1 start codon (italics) 
preceded by a mismatch of two nucleotides (underscored), and the reverse primer 
GACCGCACCGACGACTCCCGGG. After denaturation, the DNA fragment was amplified using 
PCR Platinum Supermix taq polymerase (Invitrogen), for 25 cycles (denaturation at 94°C for 30 s, 
annealing at 50°C for 1 min, and extension at 72° C for 1 min). After cloning into a PCRII cloning 
vector (Invitrogen), the amplified fragment was digested with HindIII and BstXI restriction 
enzymes and inserted into pcDNA3.1(+)hERG1, to substitute the first 500 bp of hERG1 cDNA. 
The modified hERG1 cDNA was then subcloned into pECFP-N3 after Hind III/ BamHI double 
digestion. The pECFPhERG1 functionality was tested by WB and patch-clamp experiments. 
The clone pCDNAhERG1ΔC+RD was generated according to Kupershmidt et al. (35). Briefly, a 
315 bp PCR fragment, spanning nt 3052-3366 of hERG1 cDNA, was amplified from the 
pCDNAhERG1 plasmid. The forward primer was 
GGACTCGAGCCCACCCCCAGCCTCCTCAACATCCC, with a XhoI recognition site (bold) 
inserted at the 5' end. The reverse primer was 
CTATCTAGACTACGGGGGCAGCTCCTCACACGCCATG, with a stop codon TAG (italics) 
and a XbaI recognition site (bold) inserted at the 3' end of the fragment. The amplified DNA, 
digested with XhoI and XbaI restriction enzymes, was inserted into XhoI/XbaI digested 
pCDNAhERG1 plasmid, substituting the whole C-terminal domain (aa 699-1159). The obtained 
clones were characterized by restriction pattern analysis and sequenced to verify the conservation of 
reading frame. 
WT 1 integrin (47), 1 integrin lacking the C-terminus (1-extra) (48), and the C-terminus of 1 
integrin linked to the transmembrane and extracellular part of the interleukin 2 receptor (1-cyto) 
were cloned into the Yellow Fluorescent protein Venus (YFP)-N1 vector. To generate the pYFP-N1 
vector, YFP cDNA was amplified with BamHI and NotI from the pCS2Venus vector (49), and 
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substituted to EGFP in the pEGFP-N1 vector (Clontech). The pECE-1 plasmid containing the full 
length 1A cDNA was cut with HindIII and SNABI to obtain a fragment of around 2000 bp, and 
amplified (SNAB1 and BamHI) to generate a fragment of around 400bp. The two fragments were 
cloned into the pYFP-N1 plasmid cut on HindIII/BamHI. The fragments corresponding to the 1-
extra and 1-cyto constructs were amplified and cloned into the pYFP-N1 vector cut with KpnI and 
EcoRI. 
 
Cell culture and transfection. 
Cells were routinely cultured at 37°C with 5% CO2 in either DMEM (Euroclone) (HEK 293-ICLC, 
GD25 and MDA-MB-231 cells) or RPMI (Euroclone) (HCT116 and REH cells) supplemented with 
10% fetal bovine serum (Euroclone). HEK cells expressing wild type hERG1 were as previously 
described (23). To prepare the other stably transfected cell lines, transfection was carried out with 
Lipofectamine 2000 (Invitrogen). Selection and further cell culture were performed in complete 
culture medium supplemented with geneticin (G418; Invitrogen), at 0.8 mg/ml for HEK cells, and 
2.0 mg/ml for HCT116 and MDA-MB-231 cells. For HS-FLIM-FRET experiments, HEK cells 
were transiently transfected with both pECPFhERG1 and pEYFP-β1 integrin plasmids. GD25 cells 
were transiently co-transfected with the different 1 integrin-YFP constructs and hERG1. GD25-
1-TR cells were described in (47). 
 
Preparation of cells for FRET, immunoprecipitation and patch-clamp experiments 
Cells were harvested by detaching them with 5 mM (10 mM for GD25 cells) EDTA in PBS, and 
resuspended in DMEM plus heat inactivated BSA (Fraction V, Euroclone; 250 g/ml). Next, cells 
were seeded onto dishes coated first with fibronectin (100 g/ml in serum-free medium, at 37°C for 
1 h), and then with BSA for 1h. FRET measurements started 15 min after cell seeding and 
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continued for at least 100 min, at 37 °C. When necessary (Fig. 2B), dishes coated with BSA only 
were also used. 
 
RNA extraction, reverse transcription and RT-qPCR 
RNA extraction and reverse transcription were performed as described (50). Amplification of 
KCNE1 was performed by RT-PCR with 2 μl of cDNA derived from cell lines and human heart 
RNA (Ambion®), using a commercially available master mix (Invitrogen). The primer sequences 
for KCNE1 were: 5’-TCCATTGGAGGAAGGCATTA-3’ (forward primer) and 5’-
CGCTGTGGTGTTAGACAGGA-3’ (reverse primer). PCR was performed as follows: denaturation 
at 94°C for 2 min, 35 cycles at 94°C for 30 s, 55°C for 1 min, 72°C for 30 s and a final extension 
cycle at 72°C for 10 min. The same primers were used for RQ-qPCR analysis on HEK and HCT116 
cells transfected with the KCNE1 plasmid. The SYBR green fluorescent dye (Power SYBR® 
Green, PCR master mix, Applied Biosystems) method was applied. GAPDH gene was used as a 
standard reference, as in (26). Non-transfected cell lines were used for calibration.  
 
Immunoprecipitation and immunoblotting.  
Procedures on cell lines were performed as previously described (23, 26). Cardiac and cancer 
tissues were obtained by individual donors undergoing surgery. Leukemia samples were obtained 
from bone marrow aspirates of patients at the onset of the disease. Patients were treated at the 
Molinette Hospital (Turin, Italy), at the General Surgery of the Careggi Hospital, and at the 
Hemathology Department of the Careggi Hospital (Florence, Italy). Tissues were collected after 
informed written consent, and after approval of the local Ethics Committee. All procedures were 
carried out at 4 °C. Samples were homogenized in cold protein extraction buffer (1X Cell Lysis 
Buffer) and sonicated for 30 min. For immunoprecipiation, total lysates (1.5 mg for cell line 
extracts and 0.5 mg for primary samples) were subjected to a pre-clearing step by incubating them 
with protein A/G-Plus Agarose for two hours at 4°C. Thereafter, cell lysates were 
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immunoprecipitated with the appropriate antibody at the concentrations indicated in the paragraph 
“Chemicals and antibodies”. Co-immunoprecipitation of 1 integrin and hERG1 lysates was 
performed with Mab-1. Co-immunoprecipitation of hERG1 and 1 integrin lysates was performed 
with Mab-hERG1. For both reactions, WBs were performed on immunoprecipitates and total 
lysates (“input”) from the same sample with polyclonal antibodies against hERG1 or 1. To 
determine phosphorylation (P) of Tyr
397 
in FAK, FAK was immunoprecipitated with a polyclonal 
antibody. WBs were performed on immunoprecipitates and total lysates with polyclonal antibodies 
against p-Tyr
397
 FAK, total FAK or tubulin. 
 
Densitometric analysis. 
Densitometric analysis was performed using ImageJ software (ImageJ 1.38, National Institutes of 
Health) on two different scans, after background subtraction, from at least three different 
experiments. When quantifying variations in hERG1-β1 integrin interactions, the signal for the co-
immunoprecipitated protein (for example: hERG1 when immunoprecipitating the β1 integrin, or β1 
integrin when immunoprecipitating hERG1) was first divided by the signal of the protein used for 
immunoprecipitation (for example: β1 integrin or hERG1), and then normalized to the signal of the 
corresponding protein in the total lysate (named “input hERG1”, “input β1”). The resulting value is 
indicated as “hERG1/β1 integrin complex” throughout the manuscript and in the figures. FAK 
phosphorylation was measured in immunoprecipitates with FAK antibodies, first dividing the signal 
for Tyr
397
 of FAK by the signal of the immunoprecipitated FAK, and then normalizing this value to 
the amount of FAK in the total lysate (input FAK). 
 
Flow cytometry. 
Expression of wild-type and mutant hERG1 was assessed by FACS Canto flow cytometer as in 
(28). Acquisition and analysis were performed using FACS Diva software (BD Biosciences). 
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Values are expressed as Mean Fluorescence Intensity (MFI) fold changes compared to non-
transfected HEK or MDA-MB-231 mock-transfected cells. 
 
HS-FLIM-FRET experiments 
We used a Multiphoton Microscope consisting of a Nikon TE2000-U inverted optical microscope, 
equipped with a Nikon PCM2000 Confocal Laser Scanning Unit, modified to allow the use of an 
Ultrafast Laser Source, equipped with a dichroic short-pass filter, suitable for multiphoton operation 
(650DCSPXR; Chroma Inc.). This system is made up of a mode locked Ti:Sapphire oscillator (Mira 
900 F; Coherent Inc.) pumped by a frequency doubled Nd:YVO4 laser system at 532 nm, 5W 
(Verdi V5; Coherent Inc.). Emission is tunable in the range 700–980 nm, with typical pulse 
duration of 130 fs and 76 MHz repetition rate. The laser beam, after passing through a Faraday 
isolator (to prevent part of laser beam returning to the laser cavity), was directly coupled to the 
confocal scanning unit. The confocal head is supplied with two output fluorescence emission 
channels (51). For the measurements, the light emitted from the sample was sent to a spectrograph, 
coupled to a fast 16-channel photon counting photomultiplier, with a typical transit time spread of 
150 ps (PML-16C; Becker & Hickl GmbH). A two-photon cut-off filter (BG39; Schott GmbH) was 
inserted in the fluorescence path in order to remove unwanted back-reflection of the laser light. 
Acquired signals were processed by the FLIM apparatus, which is based on Time-Correlated 
Single-Photon Counting (TCSPC) and allows the measurement of the fluorescence decay curve for 
each image pixel. Its core element is an SPC-830 module (Becker & Hickl GmbH) able to measure 
the arrival time delays of individual photons with respect to a synchronization pulse train, provided 
by the signal of a fast photodiode (PHD-100; Becker & Hickl GmbH) that detects a laser light 
reflection from the neutral density filter. Curve fitting with exponential decay curves to the 
measured data and displays of the results was performed by the software SPCImage (Becker & 
Hickl GmbH). 
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The specificity and sensitivity of the FLIM technique to detect FRET in cells was tested using HEK 
transiently co-transfected with β1 integrin-EYFP and hERG1-ECFP, either as single or as double 
transfectants (Fig. S3). The theoretical expressions used are described in Supplementary Materials 
and Methods, paragraph “Analysis of HS-FLIM-FRET data”. FLIM measurements can be affected 
by pH, temperature, previous prolonged exposure to radiation and ion concentration. Spectral 
control is thus essential, especially when performing FLIM experiments in living cells. The details 
of our procedure are given in the Supplementary Materials and Methods (“Analysis of HS-FLIM-
FRET”) and legends to Figs. S4 and S5. 
 
FRET by acceptor photobleaching experiments 
We used a custom-made confocal microscope equipped with a spinning disk unit, as previously 
described (52), and further detailed in the Supplementary Materials. FRET was detected by an 
increase of the donor signal on acceptor bleaching. From the ratio of the donor fluorescent 
emissions before and after acceptor photobleaching, the pixel-by-pixel value of FRET transfer was 
determined. The percentage of FRET events, which reflected the abundance of hERG1/1 integrin 
complexes, was estimated as the number of pixels for which FRET was detected in relation to the 
number of pixels in which the 1 integrin signal was simultaneously recorded. A detailed 
description of data acquisition and analysis is also reported in the Supplementary Materials, in 
which flowcharts are included for image acquisition and processing steps. Data analysis was 
performed using MATLAB (The MathWorks). Experiments were performed on HEK cells 
expressing wild-type hERG1, hERG1-R531C, or hERG1-K525C cultured for 45 min on 
fibronectin-coated slides. Cells were fixed with 4% paraformaldehyde and labeled with Alexa-
conjugated Mab-hERG1 and Mab-1. Purified Mab-hERG1 and Mab-1 were labeled using the 
Alexa Fluor 488 and 546 Protein Labeling Kits (Molecular Probes), respectively. Quantitative 
estimation of labeled antibodies was determined by electrophoresis in agarose gel and Coomassie 
Brilliant Blue staining. 
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Patch-clamp recording 
IhERG1 was recorded in the whole-cell configuration of the patch-clamp technique, at room 
temperature (~25°C), with a Multiclamp 700A amplifier (Molecular Devices), as previously 
described (53). E4031 was used at 2 μM. Background currents and leakage were measured in the 
presence of E4031 and subtracted from the total current. Unless otherwise indicated, [K+]o was 5 
mM. hERG1-K525C currents were recorded in 2 mM extracellular [K+]. The activation curves for 
hERG1, hERG1Δ2-370, hERG1ΔC+RD and hERG1-G628S were determined from peak tail 
currents (Itail) at -120 mV (for 1.1 s), following 15 s conditioning potentials from 0 mV to -70 mV 
(10 mV steps, spaced 4 s apart). The holding potential (VH) was 0 mV. The activation curves for 
wild-type hERG1, hERG1-K525C and hERG1-R531C were obtained following a stimulation 
protocol similar to that used by Zhang et al. (39). From a negative VH (-80 to -120 mV), we applied 
1 s test voltages (10 mV increments), every 15 s. Test voltages (Vt) varied from -60 to +40 mV 
(hERG1), from -70 to +50 mV (hERG1-K525C), and from -30 to +70 mV (hERG1-R531C). Itail 
was elicited by repolarization to -50 mV (-80 for hERG1-K525C). The peak Itail obtained at each 
Vt’s was normalized to the maximum Itail (Imax). The relation between Itail/Imax and Vt was fit to a 
Boltzmann function with OriginPro 2015 (Origin Lab, Northampton, Massachusetts) software. 
 
In vivo experiments 
Experiments were performed at the Animal House of the University of Florence (CESAL). Mice 
were housed in filter-top cages with a 12-hour dark-light cycle, and had unlimited access to food 
and water. Procedures were conducted according to the laws for experiments on live animals 
(Directive 2010/63/EU), and approved by the Italian Ministry of Health (1279/2015-PR). 
For subcutaneous xenografts, female nude mice (Harlan Laboratories) aged five to six weeks were 
injected subcutaneously in either flanks with 2 × 106 cells, resuspended in 50 l ice-cold PBS and 
gently mixed with the same volume of ice-cold Matrigel. The following human cell lines were used: 
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HEK-hERG1, HEK-hERG1-G628S, HEK-hERG1-R531C and HEK-hERG1-K525C. Each 
experimental group comprised 3 mice. One group of mice injected with HEK-hERG1 was treated 
daily with E4031 (20 mg/Kg), injected into the peritoneum, for two weeks, starting the day after 
inoculum. The volume of tumor masses measured at the sacrifice (six weeks after inoculation) was 
calculated by applying the ellipsoid equation. 
For breast orthotopic xenografts, female SCID mice (Harlan Laboratories) aged six weeks were 
injected in both fourth mammary fat pads (5 mice/group), with different cell types (2 × 106 cells per 
mouse): MDA-MB-231-hERG1, MDA-MB-231-hERG1-R531C or MDA-MB-231-hERG1-K525C. 
After injection, mice were monitored daily to ensure they did not show any signs of suffering or 
disease (such as weight loss, abdominal distension, or impaired movement). Five weeks after 
injection, mice were euthanized and tumor masses and tissues were collected and processed for 
histological analysis. The volume of tumor masses at the sacrifice was calculated by applying the 
following expression: 0.52 x lmin
2 x lmax, where  lmin and lmax are, respectively, the minimum and 
maximum measured length of the tumor mass. Hemotoxylin&Eosin (H&E) and immunostaining of 
lung metastases were performed as in (26). To quantify the metastatic burden images were acquired 
on a Leica DM 4000B microscope with a Leica DFC 320 camera using Leica QWin software 
(Leica Microsystems; Milan, Italy). The percentage of metastatic areas per microscopic field were 
determined as in (54). At least three fields per mouse lung and both lungs were examined.  
 
Statistical analysis. 
Unless otherwise indicated, data are given as mean values ± standard error of the mean (SEM), with 
n indicating the number of independent experiments. Statistical comparisons were performed with 
OriginPro 2015 and SAS 9.2 (SAS Institute, Cary, North Carolina) software. The normality of data 
distribution was checked with Kolmogorov-Smirnov (K-S) test. In the case of normal distributions, 
each data set was firstly checked for variances homogeneity, using the F-Test for equality of two 
variances and the Brown-Forsythe test for multiple comparisons. For data with unequal variances, 
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the Welch correction was applied. For comparisons between two groups of data, we used the 
Student’s t test. A two-sample K-S test was performed to test whether two underlying probability 
distributions differed. For multiple comparisons, one-way ANOVA followed by Bonferroni’s post-
hoc test was performed to derive P values. As reported in Figure legends, in case of unequal 
variances ANOVA was followed by the Hochberg’s GT2 post-hoc method. In the case of non-
normal distributions, the non-parametric Kruskal-Wallis ANOVA followed by Dwass, Steel, 
Critchlow-Fligner (DSCF)’s post-hoc method was applied. The relevant P values are reported in the 
figure panels. 
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SUPPLEMENTARY MATERIALS. 
Materials and Methods 
Fig. S1. Characterization of HEK 293 and HCT116 cells transfected with KCNE1. 
Fig. S2. Co-immunoprecipitation of HEK-hERG1 cells seeded on fibronectin 
Fig. S3. Characterization of HEK CFPhERG1+β1YFP cells. 
Fig. S4. Fluorescence decay of a donor control sample. 
Fig. S5: Control experiments to validate FRET results. 
 
Fig. S6. Protocol for image acquisition of HEK 293 cells. 
Fig. S7. Background correction and FRET map calculation. 
Fig. S8. FRET efficiency as a function of the ratio of donor to acceptor. 
Fig. S9. Lymph node metastases in mice orthotopically injected with MDA-MB-231-hERG1 
and MDA-MB-231-hERG1-R531C cells 
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FIGURE LEGENDS 
 
Fig. 1. HERG1 and 1 integrin associate in human cancer tissue but not cardiac tissue. (A) 
Left panel: co-Immunoprecipitation (co-IP) of 1 and hERG1 from CRC, PC, AML and CML 
samples. Right panel: co-IP of hERG1 and  1 from CRCs, PC and one CML sample. Bottom 
panel: Western blots (WBs) of total lysates (input) from the same tumor samples for hERG1 or 1. 
Representative of 3 independent experiments. Mab, monoclonal antibody. (B) co- IP of 1 and 
hERG1 (left panel) and co-IP of hERG1 and 1 in human heart atria. Representative of at least 3 
independent experiments. Differences in the molecular weights of hERG1 bands in the various 
cancer tissues are due to differential post-translational processing (57-58).(C) Left panel: RT-PCR 
of KCNE1 and gapdh in a representative heart sample, two CRC cell lines (HCT8 and HCT116) 
and one AML cell line (FLG 29.1). Lane 1: 100 bp standard (St); lane 2: negative control (neg. 
control). Representative of 3 independent experiments. Right panel: WB of total protein lysates 
from the same samples for KCNE1 and tubulin. (D and E) co-IP of 1 and hERG1 from HEK cells 
(D) or HCT116 cells (E) transfected or not with KCNE1. Representative of 3 independent 
experiments performed in each cell line; the corresponding densitometric results are given in the bar 
graph. P values were calculated respect to HEK-hERG1 and HCT116-WT cells, respectively, 
Student’s t test. 
 
Fig. 2. FRET shows close interaction of hERG1 and β1 integrin on the plasma membrane. 
(A) Left: image in false colors corresponding to the τm shown in the lifetime histogram and 
emission spectra (black curve), for a cell showing FRET. These spectra are compared to the 
measured emission spectra for ECFP (cyan curve) and EYFP (yellow curve). Right: image in false 
colors and related histogram corresponding to fast lifetime values τf (left) and to slow lifetime 
values τs (right), for the same cell. Images are representative of 4 independent experiments, in 
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which 104 total cells were analyzed. (B) FRET measurements, expressed as donor mean lifetimes  
carried out on HEK-hERG1 cells seeded onto fibronectin ( n = 14 cells, from 3 independent 
experiments) or BSA (n = 12 cells, from 3 independent experiments). P value was calculated 
respect to cells seeded on BSA, Student’s t test. (C) Examples of lifetime images for a cell on 
fibronectin not showing FRET (top-left), for a cell on fibronectin showing FRET (bottom-left), for 
a cell on BSA not showing FRET (top-right), and for a cell on BSA showing FRET (bottom-right). 
(D) Representative raw images of donor (hERG1, left) and acceptor (1, right) (before acceptor 
photobleaching) at two different focal planes, namely ‘Bottom plasma membrane’ and ‘Z-slice 
plasma membrane’ in HEK 293 cells. Scale bar: 10 m. The intensity scale is displayed in the top 
right corner of each image. Each image is representative of 12 total images per experimental 
condition (WT and mutants). E) HERG1/1 FRET efficiency histograms of ‘bottom plasma 
membrane’ (black solid line) images (n=6 images each sampling at least 5 cells obtained from two 
different transfection experiments) and ‘Z-slice plasma membrane’ (blue solid line) images (n=6 
images each sampling at least 5 cells obtained from two different transfection experiments), filtered 
for 1 abundance (see Supplementary Materials on image processing protocol). Mean FRET 
efficiencies were 0.23 ± 0.05 (Bottom plasma membrane), and 0.24 ± 0.05 (Z-slice plasma 
membrane). The underlying distributions were not statistically different (two-sample K-S test). 
 
Fig. 3. The cytoplasmic domains of hERG1 and β1 integrin are not necessary for the complex 
assembly. (A) HERG1 currents measured in HEK cells stably transfected with the indicated 
constructs. Representative of at least 4 cells per transfection condition analyzed in 3 independent 
experiments. (B) co-IP of hERG1 and β1 using the indicated antibodies from HEK-hERG1, HEK-
hERG1Δ2-370 and HEK-hERG1ΔC+RD-expressing cells. Representative of 3 independent 
experiments; the corresponding densitometric results are given in the bar graph. Not statistically 
different, one-way ANOVA. (C) Scheme of the β1 integrin constructs used in these experiments. 
(D) IP of hERG1 from GD25 cells co-expressing the YFP-tagged constructs and hERG1. WBs were 
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performed with the YFP antibody or the hERG1 polyclonal antibody. The arrow on the left of the 
upper panel indicates the bands of β1 and β1-extra (lanes 2 and 3). Lanes 4 and 5 show two IPs of 
hERG1 from 0.5 or 1 mg of protein from β1-cyto-transfected GD25 cells. Bands corresponding to 
1-cyto at approximately 80 KDa were not detected (dotted, two headed arrow). The panel on the 
right shows WBs using YFP antibody (“input YFP”) or hERG1 polycloncal antibody (“input 
hERG1”) on the same total cellular lysates from GD25 cells co-transfected with the indicated β1 
integrin constructs and hERG1. In the top panel, the upper arrow indicates the expected molecular 
weight of YFP-conjugated β1 integrin and β1-extra (approximately 147 KDa). The lower arrow 
indicates the expected molecular weight of β1-cyto (approximately 80 KDa). All the data reported 
in D are representative of 3 independent experiments; the corresponding densitometric results are 
given in the bar graph. P values for 1-cyto were calculated respect to 1-extra-hERG1 and 1-
hERG1 cells, one-way ANOVA. (E) co- IP of β1 and hERG1 from GD25-1-TR cells, which 
stably express the β1-extra construct. Blots are representative of two independent experiments. 
 
Fig. 4. Role of hERG1 current in the macromolecular complex formation and surface 
expression of WT and mutant hERG1 proteins. 
 (A) Effect of E4031 on whole-cell WT hERG1 currents in HEK-hERG1 cells. Current traces show 
the blocking effect on tail currents at -120 mV. Bars give the average hERG1 peak current densities 
in the presence or absence of 2 M E4031 (n= 5 cells analyzed in 3 independent experiments). P 
value was calculated respect to hERG1 cells, Student’s t test. (B) co- IP of β1 and hERG1 from 
HEK-hERG1 cells seeded onto fibronectin, in the absence or presence of 40 M E4031. 
Representative of 3 independent experiments; the corresponding densitometric results are given in 
the bar graph. P value was calculated respect to hERG1 cells, Student’s t test.  (C) Membrane 
abundance of the indicated hERG1 constructs measured in HEK cells by flow cytometry, and 
expressed as Mean Fluorescence Intensity (MFI). The MFI of mock-transfected HEK cells was set 
as 1. Representative of 4 independent experiments. Not statistically different, Kruskal-Wallis 
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ANOVA with DSCF’s post hoc method. (D) Whole-cell hERG1 currents in HEK-hERG1 cells 
(upper traces) and HEK-hERG1 G628S cells (lower traces). Only the tail current at -120 mV are 
shown (conditioning potentials are given in Materials and Methods). Currents were measured in the 
presence of 40 mM extracellular K
+
. Bars give the corresponding average peak current densities, for 
hERG1 and hERG1-G628S (n=8 cells analyzed in 3 independent experiments). P value was 
calculated respect to hERG1 cells, Student’s t test. (E) co-IP of β1 and hERG1from HEK-hERG1 
and HEK-hERG1 G628S cells seeded onto fibronectin. Representative of 5 independent 
experiments; the corresponding densitometric results are given in the bar graph. Not statistically 
different, Student’s t test.  
 
Fig. 5. hERG1 gating regulates the hERG1/β1 complex formation. 
(A) Typical whole-cell current traces elicited in HEK cells stably transfected with either hERG1-
K525C, hERG1-R531C or hERG1-S620T. Representative of at least 5 cells per transfection 
condition analyzed in 3 independent experiments. (B) Comparison of the maximal current densities 
of hERG1, hERG1-K525C, hERG1-R531C and hERG1-S620T expressing HEK cells. Data are 
average peak tail current densities calculated from at least 5 cells per transfection condition 
analyzed in 3 independent experiments, at test pulses of +40 mV, +50 mV, +70 mV and +60 mV 
for hERG1, hERG1-K525C and hERG1-R531C respectively. P values were calculated respect to 
hERG1 or hERG1-R531C cells, Kruskal-Wallis ANOVA with DSCF’s post-hoc method. (C) 
Activation curves of hERG1, hERG1-K525C, and hERG1-R531C expressing HEK cells. Data 
points are normalized peak tail currents calculated from experiments as in (A). (D) co-IP of β1 and 
hERG1 from HEK 293 cells expressing hERG1, hERG1-K525C, hERG1-R531C seeded onto 
fibronectin. Representative of 3 independent experiments; the corresponding densitometric results 
are given in the bar graph. P values were calculated respect to hERG1 cells, one-way ANOVA. (E) 
Same as (D) but for hERG1-S620T. Representative of 3 independent experiments; the 
corresponding densitometric results are given in the bar graph. P value was calculated respect to 
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hERG1 cells, Student’s t test with Welch correction. (F) Probability distributions of FRET 
efficiency from confocal images of cells expressing 1 integrin and hERG1, hERG1-R531C or 
hERG1-K525C (n=6 images each sampling at least 5 cells obtained from two different transfection 
experiments), filtered for 1 abundance (see Supplementary Materials for details on image 
processing). Mean FRET values are 0.24±0.06, 0.23±0.06 and 0.24±0.06 for hERG1, hERG1-
R531C and hERG1-K525C, respectively. No statistical difference was found between all the 
distribution couples, as tested by two-sample K-S test (P > 0.05). (G) Percentage of FRET events 
for hERG1, hERG1-R531C and hERG1-K525C (assessing complex formation between hERG1 and 
1). P value was calculated respect to hERG1 cells, one-way ANOVA with Hochberg’s (GT2) 
post-hoc method. 
 
Fig. 6. Phosphorylation of Tyr
397 
in FAK is regulated by hERG1 current. 
(A) Phosphorylation (P) of Tyr
397 
in FAK in HEK cells expressing the indicated hERG1 constructs 
and treated or not with 40 M E4031, measured after cell seeding on fibronectin. Representative of 
4 independent experiments; the corresponding densitometric results are given in the bar graph. P 
values were calculated respect to hERG1 cells, one-way ANOVA.  hERG1-S620T vs hERG1 not 
significant, Student’s t test. (C) Volume of tumor masses obtained in nude mice after subcutaneous 
injection of HEK 293 cells expressing the indicated hERG1 constructs. One group of mice injected 
with HEK-hERG1 cells was treated by intraperitoneal injection of E4031. Data are relative to 6 
tumor masses for group (3 mice per group). P values were calculated respect to mice injected with 
hERG1 cells, one-way ANOVA.   
 
Fig. 7. Effects of inhibiting hERG1 currents and hERG1/1 complex formation on neoplastic 
progression. (A) Expression of the indicated hERG1 constructs transfected in MDA-MB-231 cells, 
measured as in Figure 4C. Bars show the average hERG1 MFI of 3 independent experiments. Not 
statistically different, Kruskal-Wallis ANOVA with DSCF’s post hoc method. (B) co-IP of 1 and 
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hERG1 from MDA-MB-231 cells expressing the indicated hERG1 constructs seeded onto 
fibronectin. Representative of 3 independent experiments; the corresponding densitometric results 
are given in the bar graph. P values were reported respect to hERG1 and hERG1-R531C cells, one-
way ANOVA.  (C) Phosphorylation of Tyr
397 
in FAK in MDA-MB-231 cells expressing the 
indicated hERG1 constructs. Representative of 3 independent experiments; the corresponding 
densitometric results are given in the bar graph. P values were calculated respect to hERG1 cells, 
one-way ANOVA.  (D) Table summarizing quantitative data obtained from the breast orthotopic 
xenograft model. (E) Left (Necropsy): photographs of lungs from representative animals in which 
MDA-MB-231 cells expressing the indicated hERG1 constructs were orthotopically injected in the 
breast. Middle (Lungs H&E): lung sections labeled with H&E from the same animal as in the left 
panels. Right: magnified images and sections immunostained with an antibody against human 
MHC I (hMHC I). Bars: 100 m. (F) Percentage of metastatic area and (G) number of metastatic 
clusters per microscopic field in the lungs of mice injected with MDA-MB-231 cells expressing the 
indicated hERG1 constructs. Values are averages of measurements obtained in at least 3 different 
microscopic fields in both mouse lungs in 5 mice for each injected experimental group. P values 
were calculated respect to hERG1 and hERG1-R531C cells, one-way ANOVA. 
